Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: David L. Porter, Noelle V. Frey, Jan J. Melenhorst, Wei-Ting Hwang, Simon F. Lacey, Pamela A Shaw, Anne Chew, Katherine Marcucci, Saar Gill, Alison W. Loren, Anthony R. Mato, Stephen J. Schuster, Lester Lledo, Holly McConville, Joan Gilmore, James Capobianchi, Michael D. Kalos, Stephan A. Grupp, Bruce Levine, Carl H. June
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2737070795